Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltr…
| Periodo | 2026-11 | 2026-08 | 2026-06 | 2026-02 |
|---|---|---|---|---|
| Real | — | — | $-1.21 | $-1.36 |
| Estimado | $-0.95 | $-1.38 | $-1.14 | $-0.98 |
| Sorpresa | — | — | -6.1% | -38.8% |
| Métrica | HELP | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -47.7% | -39.2% | -8.5% |
| ROA | -43.8% | -30.9% | -12.8% |
| Current Ratio | 7.75 | 2.73 | +5.02 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -43.7% | — |
| ✗Flujo de caja operativo positivo | −CA$101M | −CA$69M |
| ✗Rentabilidad sobre activos al alza | -43.7% | -25.9% |
| ✓Caja operativa/activos supera al ROA | -39.2% | ROA -43.7% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 7.75 | 21.65 |
| ✗Sin aumentar el nº de acciones | 20M | 8M |
| –Margen bruto al alza | — | — |
| –Rotación de activos al alza | — | — |
Helus Pharma Inc. cotiza a 10.55 USD y tiene una capitalización bursátil de $771M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud